Revenue Showdown: Sarepta Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.

Biotech Revenue Battle: Amphastar vs. Sarepta

__timestampAmphastar Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 20142104610009757000
Thursday, January 1, 20152515190001253000
Friday, January 1, 20162551650005421000
Sunday, January 1, 2017240175000154584000
Monday, January 1, 2018294666000301034000
Tuesday, January 1, 2019322357000380833000
Wednesday, January 1, 2020349846000540099000
Friday, January 1, 2021437768000701887000
Saturday, January 1, 2022498987000933013000
Sunday, January 1, 20236443950001243336000
Loading chart...

In pursuit of knowledge

Revenue Showdown: A Tale of Two Biotechs

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Amphastar Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have been on divergent paths. Amphastar, with a steady growth trajectory, saw its revenue increase by approximately 206% from 2014 to 2023. Meanwhile, Sarepta's revenue skyrocketed, growing by an astonishing 12,600% over the same period.

A Decade of Growth

Starting in 2014, Amphastar's revenue was more than 20 times that of Sarepta. However, by 2023, Sarepta had not only closed the gap but surpassed Amphastar, achieving nearly double the revenue. This dramatic shift highlights Sarepta's aggressive expansion and successful product launches.

The Future of Biotech

As we look to the future, the question remains: Can Amphastar regain its lead, or will Sarepta continue its meteoric rise?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025